Continuous infusion of the α7 nicotinic acetylcholine receptor agonist EVP-6124 produces no signs of tolerance at memory-enhancing doses in rats: A pharmacokinetic and behavioral study

Behavioural Pharmacology

Volumn 26, Issue 4, 2015, Pages 403-406

  Van Goethem, Nick P ^b   Prickaerts, Jos ^b   Welty, Devin ^a   Flood, Dorothy G ^a   Koenig, Gerhard ^a  

^a FORUM Pharmaceuticals   (United States)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

acetylcholine; Alzheimer's disease; cognition; episodic memory; EVP 6124; Keywords:; object recognition task; rat; schizophrenia; tolerance; 7 nAChR agonist

Indexed keywords

ENCENICLINE; 7-CHLORO-N-QUINUCLIDIN-3-YL-BENZO(B)THIOPHENE-2-CARBOXAMIDE; BUNGAROTOXIN RECEPTOR; NICOTINIC AGENT; NOOTROPIC AGENT; QUINUCLIDINE DERIVATIVE; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; COGNITION; CONCENTRATION AT STEADY-STATE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TOLERANCE; LIQUID CHROMATOGRAPHY; MALE; MEMORY; NONHUMAN; OSMOTIC MINIPUMP; RAT; RECOGNITION; TANDEM MASS SPECTROMETRY; AGONISTS; ANIMAL; ANIMAL MODEL; BLOOD ANALYSIS; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; PILOT STUDY; WISTAR RAT;

ADMINISTRATION, ORAL; ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANIMALS; BLOOD CHEMICAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG TOLERANCE; MALE; MODELS, ANIMAL; NICOTINIC AGONISTS; NOOTROPIC AGENTS; PILOT PROJECTS; QUINUCLIDINES; RATS, WISTAR; RECOGNITION (PSYCHOLOGY); THIOPHENES;

EID: 84937686189     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000134     Document Type: Article

References (10)

1. Bitner RS, Bunnelle WH, Decker MW, Drescher KU, Kohlhaas KL, Markosyan S, et al. (2010). In vivo pharmacological characterization of a novel selective ?7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease. J Pharmacol Exp Ther 334:875-886.
2. Deardorff WJ, Shobassy A, Grossberg GT (2015). Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication. Expert Rev Neurother 15:7-17.
3. Ennaceur A, Delacour J (1988). A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 31:47-59.
4. Picciotto MR, Caldarone BJ, King SL, Zachariou V (2000). Nicotinic receptors in the brain: links between molecular biology and behavior. Neuropsychopharmacology 22:451-465.
5. Prickaerts J, Steinbusch HWM, Smits JFM, de Vente J (1997). Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: effects of 7-nitroindazole and zaprinast. Eur J Pharmacol 337:125-136.
6. Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C, et al. (2012). EVP-6124, a novel and selective ?7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of ?7 nicotinic acetylcholine receptors. Neuropharmacology 62:1099-1110.
7. Stevens KE, Cornejo B, Adams CE, Zheng L, Yonchek J, Hoffman KL, et al. (2010). Continuous administration of a selective ?7 nicotinic partial agonist, DMXBA, improves sensory inhibition without causing tachyphylaxis or receptor upregulation in DBA/2 mice. Brain Res 1352:140-146.
8. Toyohara J, Hashimoto K (2010). ?7 nicotinic receptor agonists: potential therapeutic drugs for treatment of cognitive impairments in schizophrenia and Alzheimer's disease. Open Med Chem J 4:37-56.
9. Van Goethem NP, Rutten K, van der Staay F-J, Jans LAW, Akkerman S, Steinbusch HWM, et al. (2012). Object recognition testing: rodent species, strains, housing conditions, and estrous cycle. Behav Brain Res 232: 323-334.
10. Wallace TL, Porter RHP (2011). Targeting the nicotinic alpha7 acetylcholine receptor to enhance cogntion in disease. Biochem Pharmacol 82:891-903.